Specific antibodies, levofloxacin, and modulation of capsule-associated virulence in Streptococcus pneumoniae.
Tarragó
David
D
Lara
Noelia
N
Fenoll
Asunción
A
Casal
Julio
J
Giménez
María-José
MJ
Aguilar
Lorenzo
L
Sevillano
David
D
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000097:blood*; D000918:Antibody Specificity; D019540:Area Under Curve; D016667:Bacterial Capsules / Q000378:metabolism; D005260:Female; D006801:Humans; D064704:Levofloxacin; D051379:Mice; D008807:Mice, Inbred BALB C; D008826:Microbial Sensitivity Tests / Q000592:standards; D015242:Ofloxacin / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D011008:Pneumococcal Infections / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000254:growth & development / Q000276:immunology / Q000472:pathogenicity*; D014774:Virulence
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D064704:Levofloxacin; D015242:Ofloxacin